Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Anthracyclines; Cytarabine; Cytarabine; Daunorubicin; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation

Most Recent Events

  • 03 Dec 2021 Results of a network meta-analysis of data from VIALE-A, VIALE-C, AZA-001, AZA-AML-001, and DACO-016 studies presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 25 Jun 2017 Results of post hoc analysis presented at the 22nd Congress of the European Haematology Association
  • 06 Dec 2016 Results in subgroup of patients with NCCN-defined poor-risk cytogenetics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top